Evaluation and interpretation of DTI-ALPS, a proposed surrogate marker for glymphatic clearance, in a large population-based sample
DTI-ALPS can be reliably automated in large samples. The computed DTI-ALPS was associated with vascular dysfunction (vascular risk and WMH) and may provide additional complementary information about cognitive decline. The low associations with AD biomarkers suggest that DTI-ALPS may be a poor surrogate of AD.
Authors
- Val J. Lowe (ORCID: https://orcid.org/0000-0002-5612-1667)
- Clifford R. Jack (ORCID: https://orcid.org/0000-0001-7916-622X)
- Robert I. Reid (ORCID: https://orcid.org/0000-0003-2391-8650)
- Petrice M. Cogswell (ORCID: https://orcid.org/0000-0002-8128-4476)
- Jeffrey L. Gunter (ORCID: https://orcid.org/0000-0001-7813-9078)
- Nadia Meyer (ORCID: https://orcid.org/0000-0002-7423-0226)
- Scott A. Przybelski (ORCID: https://orcid.org/0009-0009-3437-3773)
- Siddhartha Satpathi (ORCID: https://orcid.org/0000-0001-5359-7793)
- Prashanthi Vemuri (ORCID: https://orcid.org/0000-0003-4286-0589)
- Ronald Carl Petersen (ORCID: https://orcid.org/0000-0002-8178-6601)
- Jonathan Graff-Radford
- Sheelakumari Raghavan
Institutions
- Mayo Clinic (US)
- WinnMed (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- Alzheimer s Research & Therapy
- Published
- 2025-08-19
- DOI
- https://doi.org/10.1186/s13195-025-01842-3
- Citations
- 9
- Primary Topic
- Cerebrospinal fluid and hydrocephalus
- Type
- article
- Field-Weighted Citation Impact
- 8.18
Funders
- Mayo Clinic
- GHR Foundation
- National Institutes of Health
- Avid Radiopharmaceuticals
- National Institute on Aging